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Abstract
Introduction. Cell penetrating peptides (CPPs) have the ability to translocate through cell membranes with high 
efficiency and therefore can introduce biological agents with pharmaceutical properties into the cell. Transportan 
(TP) and its shorter analog transportan 10 (TP10) are among the best studied CPPs, however, their effects on 
viability of and cargo introduction into colorectal cancer (CRC) cells have yet not been investigated. The aim of 
our study was to evaluate the cytotoxic effects of TP and TP10 on representative CRC lines and the efficiency 
of protein (streptavidin) and siRNA cargo delivery by TP-biotinylated derivatives (TP-biot). 
Material and methods. HT29 (early stage CRC model) and HCT116 (metastatic CRC model) cell lines were 
incubated with TP, TP10, TP-biot1, TP-biot13 and TP10-biot1. The effects of studied CPPs on cell viability and 
cell cycle were assessed by MTT and annexin V assays. The uptake of streptavidin-FITC complex into cells was 
determined by flow cytometry and fluorescence microscopy, with the inhibition of cellular vesicle trafficking 
by brefeldin A. The efficiency of siRNA for SASH1 gene delivery was measured by quantitative PCR (qPCR). 
Results. Since up to 10 µM concentrations of each CPP showed no significant cytotoxic effect, the concentrations 
of 0.5–5 µM were used for further analyses. Within this concentration range none of the studied CPPs affected 
cell viability and cell cycle. The efficient and endocytosis-independent introduction of streptavidin-FITC com-
plex into cells was observed for TP10-biot1 and TP-biot1 with the cytoplasmic location of the fluorescent cargo; 
decreased SASH1 mRNA level was noticed with the use of siRNA and analyzed CPPs. 
Conclusions. We conclude that TP, TP10 and their biotinylated derivatives can be used as efficient delivery 
vehicles of small and large cargoes into CRC cells. (Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 4, 
270–280)
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Introduction
Cell-penetrating peptides (CPPs), also known as 
peptide transduction domains (PTDs), make a new 
class of transmembrane delivery vectors with high 
pharmaceutical potential [1]. CPPs can be taken up 
by living cells and can deliver different covalently co-
upled cargoes into cells both in vitro [2] or in vivo [3, 4]. 
Among transport peptides penetratin [5], Tat-pep- 
tide [6], oligoarginine [7], and transportan (TP) [8] 
belong to the best characterized. 
TP is a 27 amino acids (aa) long chimeric peptide 
(Table 1) containing 12 aa from the amino-terminal 
part of the neuropeptide galanin and the 14 aa long 
mastoparan (Vespula lewisii wasp venom), connected 
via a lysine residue [8]. TP reveals some characteri-
stic features of both galanin and mastoparan since it 
inhibits the binding of galanin to GALR-1 receptor 
as well as modulates the activity of Gs proteins due 
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to the inhibition of GTPase activity [9]. The shorter 
analogs of TP (TP7-15) showed lower cytotoxity in 
comparison to TP, galanin and mastoparan [8]. TP10, 
a 21 aa version of TP (Table 1) has been widely stu-
died due to its high cellular uptake rate and lack of 
the inhibition of GTPase activity [10]. 
Although the uptake of different cargoes and cyto-
toxicity of many CPPs has been analyzed in various 
types of cell cultures, the effects of TP and TP10 on 
colorectal cancer (CRC) cell lines have yet not been 
investigated. Therefore, the main goal of the present 
study was to analyze the effects of TP and TP10 and 
their derivatives on the viability and cell cycle of HT29 
and HCT116 cell lines, which are related to early 
(HT29) and metastatic (HCT116) stages of CRC. 
Currently, there is no consensus on how transpor-
tan and its derivatives deliver molecules to the cell. 
Various mechanisms such as different types of endo-
cytosis as well as direct translocation via the plasma 
membrane have been proposed [11, 12]. The mode of 
internalization can depend on peptide concentration, 
size of the cargo molecule, temperature and specific 
properties of the plasma membranes of the studied 
cells [13]. The translocation can take place via the 
energy dependent or independent route and multiple 
factors have been suggested to control the balance be-
tween various internalization pathways [14–16]. Simi-
larly, some reports suggest direct translocation to the 
cell of TP10 [17, 18], whereas other studies suggest its 
endocytosis [12, 19]. Thus, we aimed to check possible 
method of TP and TP10 penetration into CRC cells 
by determining their transport ratios after inhibition 
of endocytosis with the use of brefeldin A [20–22]. 
Additionally, we used a model of cellular penetration 
based on an introduction of a large, FITC-labeled 
protein (streptavidin, M.W. = 52.8 kDa vs. 2.1 or 
2.8 kDa for TP10 and TP molecules, respectively) or 
small siRNA molecule which decreases mRNA ratio 
of SASH1 gene. Our investigation of TP and TP10 
penetration into CRC cell lines may contribute to 
the results of other studies on CPP attached to pep-
tides [23], short interfering RNA (siRNA) and DNA 
oligonucleotides [24] as well as peptide nucleic acid 
(PNA) oligomers [25].
Material and methods
All plastic labware was obtained from Sarstedt (Nümbrecht, 
Germany) and the culture reagents were obtained from 
SigmaAldrich (St. Louis, MO, USA), if not stated otherwise.
Cell lines. Human colorectal cancer cell lines HT29 (ATCC 
cat. # HTB-38) and HCT116 (ATCC cat. # CCL-247) were 
cultured at a density of 1–2 × 106 cells per 25-cm2 flask in 
McCoy (HT29) or Dulbecco’s Modified Eagle’s (DMEM) 
medium (HCT116), supplemented with 10% fetal bovine 
serum (FBS) and penicillin (100 U/mL)/streptomycin 
(100 µg/mL). Cultures were conducted at 37°C in humidified 
atmosphere containing 5% CO2. The cells were detached 
every 2–3 days with 0.25% trypsin/EDTA. The medium was 
exchanged after each passage. Cells were cultured for 24 h 
before initiation of the experiments.
Peptide and siRNA synthesis, purification and handling. 
All peptides used in this study (Table 1) were synthesized in 
the Department of Chemistry of Biological Active Molecules, 
University of Gdansk, Poland, using the Fmoc strategy of 
solid-phase peptide synthesis as described previously [26]. 
Purification and analysis of the peptides were performed with 
the use of MALDI-TOF mass spectrometer. All peptides were 
lyophilized and stored at –30°C until use. Peptide solutions at 
dedicated concentrations were prepared directly before use in 
plastic vials by the addition of 0.9% NaCl.
Lyophilized siRNA for SASH1 gene (Abcam, Cambridge, 
UK) was dissolved to 10 µM stock in nuclease-free water (A&A 
Biotechnology, Gdynia, Poland). The vials were stored at –80°C 
until further use.
Assessment of CPP cytotoxicity. The MTT assay, a colorimet-
ric method for measuring the activity of mitochondrial succinate 
dehydrogenase in living cells, was used for the cytotoxicity 
assessment according to previously described procedure [27] 
with some modifications [28]. In brief, HT29 or HCT116 cells 
were seeded in 96-well plates to a density of 10 000 cells/well 
in 0.2 mL of above-specified culture media. After 24 h following 
concentrations [µM] of CPPs were added to wells: 0.05, 0.1, 
0.5, 1, 5, 10, 25, 50. As a negative control cells were treated 
with 0.9% NaCl. After 2 h of incubation (5% CO2, 37°C), 15 µL 
MTT solution was added into each well to reach the final con-
Table 1. Amino acid sequences of cell-penetrating peptides used in the study
CPP abbreviation Sequence Length [aa]
TP GWTLNSAGYLLGKINLKALAALAKKIL-amide 27
TP-biot1 biotin–GWTLNSAGYLLGKINLKALAALAKKIL-amide 27
TP-biot13 GWTLNSAGYLLGK(biotin)INLKALAALAKKIL-amide 27
TP10 AGYLLGKINLKALAALAKKIL-amide 21
TP10-biot1 biotin–AGYLLGKINLKALAALAKKIL-amide 21
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centration of 10 mg/mL. After further incubation for 2 h (5% 
CO2, 37°C) the cells were centrifuged at 20 817 g for 3 min at 
4°C and the medium was removed. Formazan crystals present 
in mitochondria of metabolically active cells were solubilized 
with 100 μL of dimethylsulfoxide (DMSO), and the dye con-
centration was measured using the EL × 800 Microplate Reader 
(BioTek, Highland Park, IL, USA) at 570 nm wavelength.
Cell cycle analysis. Propidium iodide (PI) DNA incorporation 
was used to evaluate DNA content in HT29 and HCT116 cells. 
Briefly, 3 × 105 cells were seeded in a 6-well plate and incubated 
(5% CO2, 37°C) in above-specified culture media for 24 h. After 
medium exchange, cells were incubated with analyzed CPPs at 
0.1 µM or 5 µM final concentrations for 24 h (5% CO2, 37°C). 
As a negative control 0.9% NaCl was used. After incubation, 
cells were harvested with trypsin, washed twice with cold 
phosphate-buffered saline (PBS, each time the centrifugation 
conditions were 400 g for 5 min at room temperature). Then cells 
were fixed gently by adding 75% EtOH and placing at –20°C. 
After 24 h, EtOH was removed by centrifugation in 400 g for 
5 min at room temperature and cell pellet was washed with cold 
PBS (400 g; 10 min; 4°C) and resuspended in 450 µL of PI buffer 
(50 µg/mL PI, 25 µg/mL RNase, PBS, Molecular Probes-Life 
Technologies, Carlsbad, CA, USA). After 30 min incubation at 
37°C in darkness, stained cells were analyzed with the use of 
FACScan flow cytometer (BD Biosciences, San Jose, CA, USA) 
in the Department of Pathophysiology, Medical University of 
Gdansk, Poland (courtesy of Professor J. Witkowski). WinMDI 
2.9 free software was used for data analysis. 
Apoptosis assay. Analysis was based on changes of phospha-
tidylserine localization within cell membrane using Annexin-V 
FITC Apoptosis Detection Kit I (BD Pharmingen, San Diego, 
CA, USA) according to the manufacturer’s instructions. 
Briefly, 3 × 105 cells cultured in 6-well plates for 24 h (5% 
CO2, 37°C); next they were treated with analyzed CPPs to 
a final concentration of 5 µM. After 24 or 48 h supernatant 
was removed, cells were trypsinized and washed twice with 
PBS and incubated with 5 μL of FITC-conjugated annexin V 
(anV) and PI for 15 min at room temperature. After addition of 
0.4 mL Buffer A (BD Pharmigen), cells were analyzed by flow 
cytometry. The obtained fluorescent results were divided into 
four groups, depending of the signal: anV (–), PI (–) — living 
cells; anV (+), PI (–) — early apoptosis; anV (+), PI (+) — late 
apoptosis; anV (–), PI (+) — cellular debris (further omitted 
in final calculation).
Protein cargo delivery with the use of biotinylated deriv-
atives of TP and TP10. Streptavidin conjugated with FITC 
(strept-FITC) was used as a cargo molecule in this experiment. 
Biotinylated CPPs (Table 1) were used in this study since the bi-
otin-steptavidin bonds are known as one of the strongest between 
biologically active molecules (Kd ≈ 10−14 mol/L) [29]. The strept-
FITC-CPP complexes were obtained by the incubation of 50 µL 
of TP-biot1, TP-biot13 or TP10-biot1 (all at 20 µM concentra-
tion) with 50 µL of 5 µM strept-FITC in the above-specified 
serum-free media, for 30 min at 25°C. Cells cultures at the den-
sity of 3 × 105, on 6-well plate were treated for 2 h at 25°C with 
strept-FITC-CPP complex to a final concentrations of 0.5/2 µM 
strept-FITC/CPP or 1.0/4.0 µM strept-FITC/CPP. Thereafter, 
cells were washed with PBS, trypsinized, washed twice with 
PBS and the cell culture serum-free media were added. The 
transport of streptavidin-FITC into cells was also assessed with 
the use of non-biotinylated TP and TP10 at the concentration 
of 0.25 µM strept-FITC/CPP complex. The following controls 
were prepared: negative — cells with 0.9% NaCl added; CPP 
without FITC — cells incubated with TP-biot1, TP-biot13 or 
TP10-biot1 at a final concentration of 2 or 4 µM; strept — cells 
incubated only with strept-FITC at a final concentration 0.5 µM 
or 1 µM. Samples were divided into two vials and first set was 
analyzed by flow cytometry to quantify the FITC signal. The 
second set of samples was placed on microscopic glass slides 
and immediately observed by fluorescence microscopy (Nikon 
Eclipse 800 microscope, Nikon, Tokyo, Japan). The images 
were acquired with Hamamatsu camera (model no. C47-42-95) 
at 494 nm wavelength and archived.
Inhibition of endocytosis by brefeldin A. To check if incor-
poration of strept-FITC-CPP complex into the cells occurred 
by endocytosis, the cellular vesicular traffic was inhibited with 
the use of brefeldin A [30]. Briefly, cells were incubated for 1 h 
(5% CO2, 37°C) in serum-free cell media containing 10 µg/mL 
brefeldin A. Thereafter, cells were washed with PBS, tryp-
sinized, washed twice with PBS and the cell culture serum-free 
media were added. Then cells were processed to measure the 
transport of the strept-FITC-CPP complexes by flow cytometry 
as described above for streptavidin delivery protocol.
siRNA cargo delivery. SASH1 gene has been chosen as a target 
for siRNA delivery by using TP or TP10, since our prelim-
inary data showed a stable expression of this gene in HT29 
and HCT116 cells. We used a procedure described by Ezzat et 
al. [31]. Cells were seeded into 24-well plates at a density of 
50 000 cells/well in 1 mL of medium. After 24 h incubation at 
37°C, siRNA was added into each well at the concentrations 
of 10 or 50 nM. CPPs (TP, TP-biot1, TP10 and TP10-biot1) 
were added to a final concentration of 2 µM to each well con-
taining cells and siRNA. All assays were run in triplicate. The 
cells were then incubated (5% CO2, 37°C) for 12, 24 and 48 h. 
After incubation, cell pellet was obtained by centrifugation at 
20 817 g for 5 min at 4°C, and the cells were stored at –80°C. 
mRNA was extracted with the use of modified Chomczyn ski- 
-Sacchi phenol-chloroform method (Total RNA Mini kit, A&A 
Biotechnology, Gdynia, Poland) and eluted with 70 µL of 
RNAse-free water, followed by RNA purity and concentration 
measurement (NanoDrop ND1000, Thermo Fisher Scientific, 
Fitchburg, WI, USA). 1 µg of total RNA was reversibly tran-
scribed (RevertAid kit, Fermentas-Thermo Fischer Scientific) 
at 42°C for 60 min, The resulting cDNA was quantified by 
qPCR (StepOnePlus, Life Technologies-Applied Biosystems, 
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Grand Island, NY, USA). The primers’ sequences for GAPDH 
(reference gene [32]) are: 5’-CTGTTCGACAGTCAGCCG-
CATC and 5’-GCGCCCAATACGACCAAATCCG, and for 
SASH1 gene: 5’-GATACGCAGAGGACTTGGATCAGC and 
5’-ATGGGCAGACCGATGGAAATGAG. The qPCR reactions 
were carried out in triplicate in 10 µL sample which contained 
1 µL of four-times diluted cDNA and SybrGreen No ROX kit 
(BioLine, London, UK) using the following protocol: 2 min at 
95°C; 40 cycles of (5 s at 95°C, 10 s at 59°C, 15 s at 72°C, 10 s 
at 77°C — fluorescence read). Dynamic melt curve analyses 
from 60°C to 95°C were conducted. Negative control containing 
water instead of cDNA as well as positive control with cDNA 
from untreated cells were added to each run. Data were archived 
using StepOne Software ver. 2.2 (Life Technologies-Applied 
Biosystems).
Statistical analysis. Statistica 10 software (StatSoft, Tulsa, 
OK, USA) was used for statistical analysis. Data represent 
mean values ± standard deviation (SD). Since partial values 
did not pass D’Agostino normality test, we used non-para-
metric Mann-Whithey U test and Kruskal-Wallis ANOVA. 
Microsoft Excel 2013 (Microsoft Corp., Redmond, WA, 
USA), GraphPad Prism 6 (GraphPad Software Inc., La Jolla, 
CA, USA) were used for the generation of plots. P < 0.05 (*) 
and p < 0.01 (**) were considered as statistically significant.
Results
Cytotoxic effects of TP, TP10 and their biotinylated 
derivatives on HT29 and HCT116 cells
The viability of HT29 and HCT116 cells incubated 
with various concentrations of TP, TP10, TP10-biot1, 
TP-biot1 and TP-biot13 was assessed by the MTT 
assay (Figure 1). Since 5 to 10 µM concentration 
range of any CPP did not substantially affect viabi-
lity of CRC cells (Figure 1), hence CPPs in a con-
centration range of 0.1–5 µM were used in further 
experiments. The 10 µM concentration of TP, TP10 
and their biotinylated derivatives can be treated as 
a common cytotoxic border for the analyzed CRC 
cell lines. 
Based on viability-regression curves, we also cal-
culated CPP lethal doses (LD) sufficient to kill 50 
or 90% CPP-treated cells (LD50, LD90, Table 2). 
Similar sensitivity to the studied CPPs were observed 
in both cell lines after 24 h incubation. Slightly higher 
cytotoxicity was observed for TP and TP10 biotiny-
lated at position 1 (TP-biot1, TP10-biot1, Table 2). 
The least cytotoxic CPP in both analyzed cell lines was 
TP-biot13 which hardly affected cell viability; LD90 
value was calculated far beyond applied TP-biot13 
concentrations (Figure 1C, Table 2). 
Influence of CPPs on cell cycle progression  
and induction of apoptosis
HT29 and HCT116 cells were incubated for 24 h with 
CPPs at 0.1 and 5 µM concentrations and the possible 
alterations of cell distribution in different cell cycle 
phases in comparison to untreated (control) cells were 
analyzed by flow cytometry. No significant changes in 
cell cycle phases were observe in HT29 and HCT116 
cells incubated for 24 h with CPPs at 0.1 and 5 µM con-
centrations (data not shown). Some delicate alterations 
concerning the percentage of apoptotic cells were, 
however, observed in HCT116 cells (Figure 2C, D). 
Cells of both lines treated for 24 h with TP10-biot1 
and TP-biot1 revealed slightly reduced percentage of 
living cells and increased percentage of early or late 
apoptotic cells compared to control ones. To check if 
prolonged incubation with the highest used concentra-
tion of CPPs (5 µM) can induce apoptosis of CRC cells 
we incubated the cells for up to 48 h (Figure 2B, D). 
Although in both HT29 and HCT116 cells cell via-
bility decreased and the percentage of early and late 
apoptotic cells increased, these changes were not si-
gnificant. The only significant decrease in the viability 
of HT29 and HCT116 compared to control cells was 
observed in cells incubated for 48h with TP10-biot1 
(Figure 2B, D).
Delivery of FITC-labeled streptavidin into  
cells by biotinylated TP and TP10
Delivery of strept-FITC was performed to check if lar-
ge protein cargo can be introduced into cells with the 
use of TP-biot1, TP-biot13 and TP10-biot1 (Figure 3). 
Since one streptavidin molecule binds four biotin 
molecules [29], for quantitative analysis two different 
concentrations of biotinylated CPPs were used: 2 and 
4 µM which corresponded to 0.5 and 1 µM streptavidin 
concentration. 
The efficient delivery of strept-FITC into HCT116 
cells with the use of studied biotinylated derivatives 
was observed after 2 h of incubation with 4 µM CPP 
(Figure 3B). The significant increase of fluorescent 
signal was observed for TPbiot1 at 4 µM CPP concen-
tration. In relation to control cells the fluorescence 
signals in HT29 were 7 times higher, while in HCT116 
were 4 times higher. For TP10-biot1 comparable 
efficiency of delivery rate at 4 µM concentration was 
observed only in HCT116 cells but not in HT29 cells 
(Figure 3B).
On the contrary, TP-biot13 was found to be ineffec-
tive in delivery of CPPs, since no successful delivery at 
2 µM CPP into HCT116 cells could be observed. The 
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Figure 1. Effects of transportan and its derivatives on the viability of HCT116 and HT29 cells. Cells were incubated with 
various concentrations of transportan (TP) and its derivates for 24 h and cell viability was assessed by MTT assay as de-
scribed in Methods. Plots present mean ± SD from 3 independent experiments. Circles and squares correspond to HT29 
and HCT116 cells, respectively. X axis represents CPP concentration in logarithmic scale; for 5 and 10 µM concentrations 
of CPPs vertical dotted lines were plotted. Y axis represents cell viability expressed as a percentage relative to the untreat-
ed control cells incubated without CPPs. Linear regression lines were plotted for both HT29 (dashed line) and HCT116 
(solid line) cell lines. Lines’ equations are not shown
A B
C D
E
comparatively small, but statistically significant increase 
in fluorescent signal for TP-biot13 was observed only at 
4 µM concentration in HCT116 cells (Figure 3A). No 
fluorescent signal was noticed when the combination 
of strept-FITC with sole TP or TP10 were used. The 
negative controls of cells treated only with strept-FITC 
or CPPs also showed no signal (data not shown).
Endocytosis is not involved in the streptavidin 
transport by CPPs
The possible involvement of endocytosis and other 
vesicle-based cellular trafficking pathways in strep-
tavidin introduction into the studied CRC cells were 
blocked with the use of brefeldin A. Since TP-biot13 
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showed poor delivery rate (Figure 3), only on TP-biot1 
and TP10-biot1 were studied. The intracellular trans-
port of strept-FITC-CPP conjugate was not inhibited 
by brefeldin A treatment. Although the increased 
fluorescent signal for TP-biot1 at 4 µM concentration 
was lower after incubation with brefeldin A than 
without endocytosis inhibition (5-fold vs. 7-fold signal 
in HT29 and 3-fold vs. 4-fold signal in HCT116 cells) 
(Figures 3 and 4), it was significantly higher than in 
control cells. Moreover, the efficiency of transport 
across the plasma membrane was proportional to 
CPP concentration (Figure 4). Comparable efficien-
Figure 2. Apoptosis-inducing capability of transportan and its derivates in HT29 and HC116 cell lines. HT29 (A–B) and 
HCT116 (C–D) cells were incubated with transportan (TP) and its derivates at the concentration of 5 µM for 24 or 48 h. 
Apoptosis was assessed by Annexin V FITC Apoptosis Assay as described in Methods. Bars (mean ± SD) represent: live 
cells (chequered pattern); late apoptotic cells (black); early apoptotic cells (dark grey). *, f refer to statistically significant 
differences between viable cells of control sample or sample treated with TP10 vs. its biotinylated derivative, respectively 
(p < 0.05; Kruskal-Wallis ANOVA test)
A B
C D
Table 2. Lethal doses of the studied CPPs
CRC cell line Lethal dose Cell penetrating peptides [µM]
TP TP-biot1 TP-biot13 TP10 TP10-biot1
HT29 LD50 17.99 17.75 38.52 26.62 12.82
LD90 36.54 43.35 80.65 43.81 39.97
HCT116 LD50 24.19 19.15 31.13 22.82 16.87
LD90 43.38 41.16 68.83 41.95 38.46
LD50, LD90 — concentration of CPP that is sufficient to kill 50 or 90 percent of cells within 24 h. LD50 and LD90 concentration values were calculated 
using interpolation based on a regression line plotted in Figure 1. LD90 values were written in italics
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A
B
Figure 3. CPP-mediated streptavidin-FITC delivery to HT29 (A) and HCT116 (B) cells. Cells were incubated for 2 h 
without (dotted bars) or with CCP and streptavidin-FITC at the ratios of 2/0.5 µM (hatched bars) or 4/1 µM, (crossed bars), 
respectively. Bars represent fluorescent values (mean ± SD) of three independent experiments. *, ** refer to significant 
differences between cells incubated with CPP-streptavidin-FITC and control cells (p < 0.05 and p < 0.01, respectively; 
Mann-Whitney U test)
Figure 4. Influence of endocytosis inhibition on cargo introduction into HT29 (A) and HCT116 (B) cells. Cells were incu-
bated with 10 µg/mL brefeldin A for 1 h before addition of streptavidin and CPPs as described in Methods. Bars represent 
fluorescent values (mean ± SD) of three independent experiments. *,** refer to significant differences between cells 
incubated with CPP-streptavidin-FITC complex and control cells; p < 0.05 and p < 0.01, respectively; Mann-Whitney U 
test. Experiments did not include TP-biot13 due to its low efficiency of cargo introduction as shown in Figure 3
A
B
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cy of TP10-biot1 mediated transport of streptavidin 
complex with or without brefeldin A was observed 
(Figures 3 and 4). These results show that endocytosis 
was not involved in the mechanisms of large protein 
cargo delivery into CRC cell lines by TP-biot1 and 
TP10-biot1.
Intracellular localization of streptavidin-FITC/ 
/TP-biot1 intracellular complex
Based on the highest delivery rate of streptavidin 
conjugated with TP-biot1 into HT29 cells compa-
red to control cells (Figure 3A), we performed the 
qualitative study of cellular location with the use of 
fluorescent microscopy. Since the concentrations of 
CPPs/strept-FITC used for quantitative studies showed 
very intense fluorescence signal (data not shown), we 
had to decrease concentration down to 1/0.25 µM TP
-biot1/strept-FITC and shorten the incubation time to 
1 h. The fluorescence clusters were deposited on the 
cytoplasmic side of the plasmalemma, as well as they 
were bound to intracellular membranes (Figure 5A, B).
CPP-mediated siRNA delivery into cells 
The efficiency of siRNA delivery was checked by 
measurement of intracellular SASH1 mRNA levels 
in comparison to control cells with the use of qPCR 
technique (Figure 6). CRC cells were incubated with 
siRNA for SASH1 mRNA at 10 or 50 nM concentra-
tion in a presence of CPPs. Based on the results of the 
streptavidin delivery into the cells and due to shortage 
Figure 5. Streptavidin-FITC delivery into HT29 cells with the use of TP-biot1. Cells were incubated with 1 µM TP-biot1 
and 0,25 µM strept-FITC for 1 h. Fluorescence microscopy was performed as described in Methods. The streptavi-
din-FITC complexes bound to plasma membranes are pointed with dotted arrows, whereas solid arrows show streptavi-
din-FITC clumps in cytoplasm. Control cells incubated only with streptavidin-FITC did not show any fluorescent signal 
(not shown). Objective magnification: × 10 (A) and × 20 (B)
Figure 6. Efficiency of siRNA delivery into CRC cell 
lines with CPP assistance. HT29 and HCT116 cells were 
incubated for 12, 24 or 48 h with siRNA (50 nM) and CPPs 
at the concentration of 2 µM. Total RNA isolation from 
all cells followed by reverse transcription was described in 
Methods. SASH1 mRNA levels were assessed by qPCR 
and normalized to GAPDH mRNA content in each sample, 
followed by calibration to control cells which were set to 1.  
Bars represent mean ± SD SASH1 expression values mea-
sured at all-time points (12, 24 and 48 h) in three replicates 
for each time-point. *significant differences between con-
trol and treated cells; p < 0.05 (Mann-Whitney U test)
A B
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of available siRNA, we did not use TP-biot13 in this 
experiment. No differences were observed in mRNA 
expression ratio when 10 nM siRNA was used (data 
not shown). Significant decrease of SASH1 mRNA 
content were observed when HT29 and HCT116 
cells were preincubated with 50 nM siRNA before 
CPPs were added (with one exception — TP-biot1 in 
HCT116 cells). Simultaneously, no significant changes 
in the SASH1 mRNA levels were observed in cells 
treated only with CPPs or siRNA (Figure 6). 
Discussion
The ability to cross the cellular lipid bilayer and access 
the cell interior is still one of the major obstacles to 
overcome in order to progress current drug develop-
ment. Therefore, various techniques have been deve-
loped in order to improve cellular uptake of bioactive 
agents [33]. CPPs are the promising factors which 
can improve the introduction of bioactive substances 
into tumor cells [18]. To date, the CPPs-mediated 
cargo delivery in in vitro conditions has been widely 
studied [9]; however, just few studies were perfor-
med on CRC-derived cell lines. E.g. the efficiency 
of cargo introduction by TAT into HT29 [34] and 
BR2 into HCT116 cells was reported [35]. Our study 
is the first focused on the effects of TP, TP10 and 
their biotinylated derivates on cell viability and large 
protein cargo delivery into early-staged HT29 and 
metastatic colorectal cancer HCT116 cells. Moreover, 
we established the concentration ranges of TP, TP10 
and their biotinylated derivatives which affected cell 
viability and induced apoptosis. In model cancer cell 
lines, HeLa and CHO (hamster ovarian cancer) cells 
appeared to be more sensitive to TP (LD50 = 4 and 
10 µM, respectively) [36].
Interestingly, our observation of similar effects of 
TP and TP10 on cell viability and cell cycle progression 
is puzzling since TP was shown to strongly down-re-
gulate GTPase activity followed by decreased cell 
viability, due to the presence of full-mastoparan sequ-
ence, whereas TP10 had no effect on this enzyme [8]. 
Our findings could be explained by the reported up
-regulation of KRAS protein (protein with GTPase 
activity) in HT29 cells [37] and Ras-GTP-activating 
protein in HCT116 cells [38] which may overcome the 
GTPase inhibitory effect of TP. On the other hand, 
the observed higher cytotoxic effect of TP10-biot1 as 
compared to TP-10 during prolonged incubation (up 
to 48 h) with HT29 and HCT116 cells might be caused 
by increased pore formation in plasma membrane and 
induction of apoptosis [39].
Despite of cytotoxic effect exerted at concentra-
tions higher than 18 µM for TP and 23 µM for TP10, 
those CPPs are still one of the foremost studied 
agents due to their high delivery ratio at non-toxic 
concentrations [40]. The main goal for all CPPs in 
cancer cell studies is to deliver anticancer agents into 
cytoplasm/nucleus without causing damage to the cell 
membrane. Recently, siRNA [41], plasmid DNA [34], 
PNA [42] or PMO (Morpholino oligomers) [43] 
agents have been intensively studied in order to trigger 
specific cellular responses via up or down regulation 
of gene expression. Moreover, CPPs were used for the 
induction of direct cellular death by the introduction 
of doxorubicin [44] or anti-cancer drug paclitaxel [45] 
into the cancer cells. Intriguingly, Song and colleagues 
observed that TP10 and its analogs preferentially en-
tered cancer cells rather than normal cells [18]. The 
phenomenon of the uptake selectivity toward cancer 
cells could make TP10 and its analogs potent CPPs 
for drug delivery to these cells. Recently, the effects of 
a fusion peptide that contained the TP-bound LXXLL- 
-motif of the human SRC-1 nuclear receptor box 1 
was investigated in vitro in breast cancer cells line. 
This peptide induced dose-dependently cell death of 
breast cancer cells and this effect was not influenced 
by estrogen receptor (ER) status. It reduced also the 
viability and proliferation of hormone-unresponsive 
breast cancer MDA-MB-231 cells [46]. 
All the mentioned cargoes were characterized by 
small molecular masses and were covalently bound 
to CPPs which modified the molecular conformation 
of CPPs by the formation of disulfide bridges. The 
specific feature of our study, as opposed to the other 
ones, was to introduce large protein into cancer cells 
by establishing non-covalent bonds with the studied 
CPPs (CPP-biotin-streptavidin complex) [47].
Despite of the effective streptavidin delivery with 
the use of TP-biot1 and TP10-biot1, inefficient in-
sertion with the use of TP-biot13 was observed. We 
suggest that steric hindrance of the streptavidin-biotin 
complex can heavily affect delivery capability of this 
TP derivative. The salt bridge between Lys13 of TP 
(or Lys7 in TP10) and phospholipids of the synthetic 
bilayer may be the key to TP transport across the pla-
sma membrane [18]. Therefore, if Lys13 in TP-biot13 
is hidden in the active site of streptavidin, then the 
occurrence of TP-plasma membrane effect may be 
less possible, due to steric hindrance. Although such 
explanation requires experimental verification, the 
positive results obtained with the use of TP-biot1 
and TP10-biot1 can be a partial confirmation of this 
hypothesis. 
Large protein delivery usually occurs by the way 
of endocytosis [25, 48]. CPP/cargo complexes reside 
then in endosomal vesicles and only a minor portion 
of them is able to escape these compartments, which 
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decreases enormously the bioavailability of the 
transported substances [49]. Räägel et al. described 
the population of complexes-containing vesicles with 
neutral pH observed during intracellular trafficking. 
Induction of vesicles with non-acidic pH could be 
crucial for the escape of CPP/cargo complexes from 
endosomal compartment [50]. On the other hand, 
CPPs may utilize two or more trafficking pathways 
depending on the experimental conditions [51]. Our 
studies refer to these observations as streptavidin 
transport by biotinylated TP and TP10 into CRC cell 
lines was independent of the endocytosis because 
brefeldin A did not inhibit this process. Brefeldin 
A was used to block cellular vesicle traffic pathways 
as it indirectly inhibits protein transport from the 
endoplasmic reticulum to the Golgi apparatus by 
preventing formation of COPI-mediated transport 
vesicles [52]. Moreover, the process of transport 
across the plasma membrane was CPP-concentration 
dependent. On the other hand, the blockage of vesic-
ular transport reduced the efficiency of delivery in the 
case of TP-biot1 (Figures 3 and 4). Thus, endocytosis 
was not the main trafficking pathway for large cargo 
delivery by TP molecules in the studied CRC cell 
lines, although a partial contribution to this process, 
especially in the case of TP-biot1 cannot be excluded. 
To our knowledge, the analysis of intracellular 
trafficking of TP-biot1-strept-FITC and TP10-biot1-
strept-FITC complexes with the use of brefeldin A 
was not performed earlier.
Our studies showed also that the introduced 
complexes of TP-biot1-strept-FITC in HT29 cells 
were bound to cytoplasmic side of plasmalemma or 
to intracellular membranes. This observation is in 
agreement with the reported location of other CPPs, 
such as TAT [53] or TP and its derivatives TP10 and 
TP14 [8].
We also checked if a small molecular mass cargo, 
siRNA, could be transported into CRC cells by analy-
zed CPPs. In theory, after successful delivery, siRNA 
should decrease the mRNA level of targeted gene, 
hence the comparison of SASH1 transcript level be-
tween control (no siRNA) and siRNA + CPP-treated 
cells should determine the efficiency of delivery. Since 
we noted the efficient decrease of intracellular SASH1 
mRNA level by SASH1-specific siRNA, we expect that 
the use of TP and its derivatives for siRNA delivery 
into CRC cell lines could be a good alternative to 
other siRNA-delivery systems, due to lack of negative 
effect on cell viability of analyzed CPPs.
In summary, we have documented that TP, TP10 
and their biotinylated derivatives can be used as 
efficient delivery vehicles of small and large cargoes 
into CRC cells.
Acknowledgments
The study was supported by the grant no. N N401 
005338 of the Ministry of Science and Higher Educa-
tion. We also thank G. Parfianowicz, Ph.D., A. Jozwik, 
Ph.D., K. Lisowska, Ph.D., and M. Stanislawowski, 
Ph.D. for excellent technical support.
References
1. Saar K, Lindgren M, Hansen M et al. Cell-penetrating pep-
tides: a comparative membrane toxicity study. Anal Biochem. 
2005;345:55–65.
2. Cardozo AK, Buchillier V, Mathieu M et al. Cell-permeable 
peptides induce dose- and length-dependent cytotoxic effects. 
Biochim Biophys Acta. 2007;1768:2222–2234.
3. Amantana A, Moulton HM, Cate ML et al. Pharmacokinetics, 
biodistribution, stability and toxicity of a cell-penetrating 
peptide-morpholino oligomer conjugate. Bioconjug Chem. 
2007;18:1325–1331.
4. Moschos SA, Jones SW, Perry MM et al. Lung delivery studies 
using siRNA conjugated to TAT(48-60) and penetratin reveal 
peptide induced reduction in gene expression and induction 
of innate immunity. Bioconjug Chem. 2007;18:1450–1459.
5. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL. 
Conjugates of antisense oligonucleotides with the Tat and 
antennapedia cell-penetrating peptides: effects on cellular 
uptake, binding to target sequences, and biologic actions. 
Pharm Res. 2002;19:744–754.
6. Begley R, Liron T, Baryza J, Mochly-Rosen D. Biodistribution 
of intracellularly acting peptides conjugated reversibly to Tat. 
Biochem Biophys Res Commun. 2004;318:949–954.
7. Futaki S, Suzuki T, Ohashi W et al. Arginine-rich peptides. 
An abundant source of membrane-permeable peptides having 
potential as carriers for intracellular protein delivery. J Biol 
Chem. 2001;276:5836–5840.
8. Soomets U, Lindgren M, Gallet X et al. Deletion analogues 
of transportan. Biochim Biophys Acta. 2000;1467:165–176.
9. Ruczynski J, Wierzbicki PM, Kogut-Wierzbicka M, Mucha P, 
Siedlecka-Kroplewska K, Rekowski P. Cell-penetrating 
peptides as a promising tool for delivery of various molecules 
into the cells. Folia Histochem Cytobiol. 2014;52. doi: 10.5603/
FHC.a2014.0034.
10. Hallbrink M, Floren A, Elmquist A, Pooga M, Bartfai T, 
Langel U. Cargo delivery kinetics of cell-penetrating peptides. 
Biochim Biophys Acta. 2001;1515:101–109.
11. Gros E, Deshayes S, Morris MC et al. A non-covalent 
peptide-based strategy for protein and peptide nucleic acid 
transduction. Biochim Biophys Acta. 2006;1758:384–393.
12. Morris MC, Deshayes S, Heitz F, Divita G. Cell-penetrating 
peptides: from molecular mechanisms to therapeutics. Biol 
Cell. 2008;100:201–217.
13. Pooga M, Kut C, Kihlmark M et al. Cellular translocation of 
proteins by transportan. FASEB J. 2001;15:1451–1453.
14. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating 
peptides: tools for intracellular delivery of therapeutics. Cell 
Mol Life Sci. 2005;62:1839–1849.
15. Padari K, Saalik P, Hansen M et al. Cell transduction pathways 
of transportans. Bioconjug Chem. 2005;16:1399–1410.
16. Saalik P, Niinep A, Pae J et al. Penetration without cells: 
membrane translocation of cell-penetrating peptides in the 
model giant plasma membrane vesicles. J Control Release. 
2011;153:117–125.
280 Piotr M. Wierzbicki et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2014
10.5603/FHC.a2014.0035
www.fhc.viamedica.pl
17. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. 
A comprehensive model for the cellular uptake of cationic 
cell-penetrating peptides. Traffic. 2007;8:848–866.
18. Fretz MM, Penning NA, Al-Taei S et al. Temperature-, con-
centration- and cholesterol-dependent translocation of L- and 
D-octa-arginine across the plasma and nuclear membrane of 
CD34+ leukaemia cells. Biochem J. 2007;403:335–342.
19. Jiao CY, Delaroche D, Burlina F, Alves ID, Chassaing G, 
Sagan S. Translocation and endocytosis for cell-penetrating 
peptide internalization. J Biol Chem. 2009;284:33957–33965.
20. Dunkin CM, Pokorny A, Almeida PF, Lee HS. Molecular 
dynamics studies of transportan 10 (tp10) interacting with 
a POPC lipid bilayer. J Phys Chem B. 2011;115:1188–1198.
21. Song J, Kai M, Zhang W et al. Cellular uptake of transportan 
10 and its analogs in live cells: Selectivity and structure-activity 
relationship studies. Peptides. 2011;32:1934–1941.
22. Madani F, Lindberg S, Langel U, Futaki S, Graslund A. 
Mechanisms of cellular uptake of cell-penetrating peptides. 
J Biophys. 2011;2011:414729.
23. Emans N, Zimmermann S, Fischer R. Uptake of a fluorescent 
marker in plant cells is sensitive to brefeldin A and wortman-
nin. Plant Cell. 2002;14:71–86.
24. Frankel G, Gil S, Dougan G. Effect of deoxymannojirimycin 
and Brefeldin A on Yersinia pseudotuberculosis invasin — 
eukaryotic cell interaction. Microb Pathog. 1995;19:421–427.
25. Veldhoen S, Laufer SD, Restle T. Recent developments 
in peptide-based nucleic acid delivery. Int J Mol Sci. 2008; 
9:1276–1320.
26. Kocic I, Ruczynski J, Szczepanska R et al. Cell-penetrating 
peptides modulate the vascular action of phenylephrine. 
Pharmacol Rep. 2011;63:195–199.
27. Eudes F, Chugh A. Cell-penetrating peptides: From mam-
malian to plant cells. Plant Signal Behav. 2008;3:549–550.
28. Siedlecka-Kroplewska K, Szczerba A, Lipinska A, Slebioda T, 
Kmiec Z. 3-Fluoromethcathinone, a structural analog of 
mephedrone, inhibits growth and induces cell cycle arrest 
in HT22 mouse hippocampal cells. J Physiol Pharmacol. 
2014;65:241–246.
29. Weber PC, Ohlendorf DH, Wendoloski JJ, Salemme FR. 
Structural origins of high-affinity biotin binding to streptavi-
din. Science. 1989;243:85–88.
30. Korber C, Horstmann H, Satzler K, Kuner T. Endocytic 
structures and synaptic vesicle recycling at a central synapse 
in awake rats. Traffic. 2012;13:1601–1611.
31. Ezzat K, Helmfors H, Tudoran O et al. Scavenger recep-
tor-mediated uptake of cell-penetrating peptide nanocom-
plexes with oligonucleotides. FASEB J. 2012;26:1172–1180.
32. Wierzbicki PM, Klacz J, Rybarczyk A et al. Identification of 
a suitable qPCR reference gene in metastatic clear cell renal cell 
carcinoma. Tumour Biol. 2014. doi: 10.1007/s13277-014-2566-9.
33. El-Andaloussi S, Jarver P, Johansson HJ, Langel U. Cargo-de-
pendent cytotoxicity and delivery efficacy of cell-penetrating 
peptides: a comparative study. Biochem J. 2007;407:285–292.
34. Saleh AF, Aojula H, Arthanari Y, Offerman S, Alkotaji M, 
Pluen A. Improved Tat-mediated plasmid DNA transfer by 
fusion to LK15 peptide. J Control Release. 2010;143:233–242.
35. Lim KJ, Sung BH, Shin JR et al. A cancer specific cell-pene-
trating peptide, BR2, for the efficient delivery of an scFv into 
cancer cells. PLoS One. 2013;8:e66084.
36. Jones SW, Christison R, Bundell K et al. Characterisation 
of cell-penetrating peptide-mediated peptide delivery. Br J 
Pharmacol. 2005;145:1093–1102.
37. Kam Y, Rubinstein A, Nissan A, Halle D, Yavin E. Detec-
tion of endogenous K-ras mRNA in living cells at a single 
base resolution by a PNA molecular beacon. Mol Pharm. 
2012;9:685–693.
38. Zhang H, Zhang S, He H, Zhao W, Chen J, Shao RG. 
GAP161 targets and downregulates G3BP to suppress cell 
growth and potentiate cisplaitin-mediated cytotoxicity to 
colon carcinoma HCT116 cells. Cancer Sci. 2012;103:1848–
–1856.
39. Barany-Wallje E, Gaur J, Lundberg P, Langel U, Graslund A. 
Differential membrane perturbation caused by the cell pene-
trating peptide Tp10 depending on attached cargo. FEBS Lett. 
2007;581:2389–2393.
40. Eggimann GA, Buschor S, Darbre T, Reymond JL. Con-
vergent synthesis and cellular uptake of multivalent cell 
penetrating peptides derived from Tat, Antp, pVEC, TP10 
and SAP. Org Biomol Chem. 2013;11:6717–6733.
41. Arukuusk P, Parnaste L, Oskolkov N et al. New generation 
of efficient peptide-based vectors, NickFects, for the delivery 
of nucleic acids. Biochim Biophys Acta. 2013;1828:1365– 
–1373.
42. Fisher L, Soomets U, Cortes Toro V et al. Cellular delivery 
of a double-stranded oligonucleotide NFkappaB decoy by 
hybridization to complementary PNA linked to a cell-pene-
trating peptide. Gene Ther. 2004;11:1264–1272.
43. Moulton HM. Cell-penetrating peptides enhance systemic 
delivery of antisense morpholino oligomers. Methods Mol 
Biol. 2012;867:407–414.
44. Nasrolahi Shirazi A, Tiwari R, Chhikara BS, Mandal D, Pa-
rang K. Design and biological evaluation of cell-penetrating 
peptide-doxorubicin conjugates as prodrugs. Mol Pharm. 
2013;10:488–499.
45. Jang YL, Yun UJ, Lee MS et al. Cell-penetrating peptide 
mimicking polymer-based combined delivery of paclitaxel 
and siRNA for enhanced tumor growth suppression. Int J 
Pharm. 2012;434:488–493.
46. Tints K, Prink M, Neuman T, Palm K. LXXLL peptide con-
verts transportan 10 to a potent inducer of apoptosis in breast 
cancer cells. Int J Mol Sci. 2014;15:5680–5698.
47. Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and 
strategies for effective delivery of antisense and siRNA oligo-
nucleotides. Nucleic Acids Res. 2008;36:4158–4171.
48. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrat-
ing peptides: from molecular mechanisms to therapeutics. 
Br J Pharmacol. 2009;157:195–206.
49. Lehto T, Simonson OE, Mager I et al. A peptide-based vec-
tor for efficient gene transfer in vitro and in vivo. Mol Ther. 
2011;19:1457–1467.
50. Raagel H, Saalik P, Hansen M, Langel U, Pooga M. CPP-pro-
tein constructs induce a population of non-acidic vesicles 
during trafficking through endo-lysosomal pathway. J Control 
Release. 2009;139:108–117.
51. Madani F, Abdo R, Lindberg S et al. Modeling the endoso-
mal escape of cell-penetrating peptides using a transmem- 
brane pH gradient. Biochim Biophys Acta. 2013;1828:1198–
–1204.
52. Nebenfuhr A, Ritzenthaler C, Robinson DG, Brefeldin A. 
Deciphering an enigmatic inhibitor of secretion. Plant Physiol. 
2002;130:1102–1108.
53. Rinne J, Albarran B, Jylhava J et al. Internalization of novel 
non-viral vector TAT-streptavidin into human cells. BMC 
Biotechnol. 2007;7:1.
Submitted: 27 November, 2014 
Accepted after reviews: 9 December, 2014 
Available as AoP: 12 December, 2014
